Psychotropic profile of S 17092, a prolyl endopeptidase inhibitor, using quantitative EEG in young healthy volunteers

Neuropsychobiology

Volumn 55, Issue 3-4, 2007, Pages 176-183

  Morain, P ^a   Boeijinga, P H ^b   Demazieres A ^b   De Nanteuil, G ^a   Luthringer, R ^b  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b FORENAP   (France)

Author keywords

Cognitive enhancer; Mood stabilizer; Prolyl endopeptidase inhibitor; Quantitative EEG

Indexed keywords

MOOD STABILIZER; PROLYL ENDOPEPTIDASE INHIBITOR; S 17092; UNCLASSIFIED DRUG;

ADULT; ALPHA RHYTHM; ARTICLE; BETA RHYTHM; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELTA RHYTHM; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; ELECTROCARDIOGRAPHY MONITORING; ELECTROENCEPHALOGRAPHY; HUMAN; MALE; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; VITAL SIGN;

ADOLESCENT; ADULT; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ELECTROENCEPHALOGRAPHY; HUMANS; INDOLES; MALE; PSYCHOTROPIC DRUGS; THIAZOLIDINES; TIME FACTORS;

EID: 34948825441     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107070     Document Type: Article

References (28)

1. Barelli H, Petit A, Hirsch E, Wilk S, De Nanteuil G, Morain P, Checler F: S 17092-1, a highly potent, specific and cell permeant inhibitor of human proline endopeptidase. Biochem Biophys Res Commun 1999;257:657-661.
2. Bellemere G, Morain P, Vaudry H, Jegou S: Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and alpha-melanocyte-stimulating hormone breakdown in the rat brain. J Neurochem 2003;84:919-929.
3. Bellemere G, Vaudry H, Morain P, Jegou S: Effect of prolyl endopeptidase inhibition on arginine-vasopressin and thyrotrophin-releasing hormone catabolism in the rat brain. J Neuroendocrinol 2005;17:306-313.
4. Marighetto A, Touzani K, Etchamendy N, Torrea CC, De Nanteuil G, Guez D, et al: Further evidence for a dissociation between different forms of mnemonic expressions in a mouse model of age-related cognitive decline: effects of tacrine and S 17092, a novel prolyl endopeptidase inhibitor. Learn Mem 2000;7:159-169.
5. Morain P, Lestage P, De Nanteuil G, Jochemsen R, Robin JL, Guez D, et al: S 17092: a prolyl endopeptidase inhibitor as a potential therapeutic drug for memory impairment - Preclinical and clinical studies. CNS Drug Rev 2002;8:31-52.
6. Schneider JS, Giardiniere M, Morain P: Effects of the prolyl endopeptidase inhibitor S 17092 on cognitive deficits in chronic low dose MPTP-treated monkeys. Neuropsychopharmacology 2002;26:176-182.
7. Morain P, Robin JL, De Nanteuil G, Jochemsen R, Heidet V, Guez D: Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers: a phase I study. Br J Clin Pharmacol 2000;50:350-359.
8. Maes M, Goossens F, Scharpe S, Meltzer HY, D'Hondt P, Cosyns P: Lower serum prolyl endopeptidase enzyme activity in major depression: further evidence that peptidases play a role in the pathophysiology of depression. Biol Psychiatry 1994;35:545-552.
9. Maes M, Goossens F, Scharpé S, Calabrese J, Desnyder R, Meltzer HY: Alterations in plasma propyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs. Psychiatry Res 1995;58:217-225.
10. Maes M, Goossens F, Lin A, De Meester I, Van Gastel A, Scharpe S: Effects of psychological stress on serum prolyl endopeptidase and dipeptidyl peptidase IV activity in humans: higher serum prolyl endopeptidase activity is related to stress-induced anxiety. Psychoneuroendocrinology 1998;23:485-495.
11. Williams RS, Eames M, Ryves WJ, Viggars J, Harwood AJ: Loss of a prolyl oligopeptidase confers resistance to lithium by elevation of inositol (1,4,5) trisphosphate. EMBO J 1999;18:2734-2745.
12. Williams RS, Harwood AJ: Lithium therapy and signal transduction. Trends Pharmacol Sci 2000;21:61-64.
13. Harwood AJ, Agam G: Search for a common mechanism of mood stabilizers. Biochem Pharmacol 2003;66:179-189.
14. Cheng L, Lumb M, Polgar L, Mudge WA: How can the mood stabilizer VPA limit both mania and depression? Mol Cell Neurosci 2005;29:155-161.
15. Saletu B: Pharmacodynamics and EEG: advances in pharmaco-EEG; in Krijzer F, Hermann WM (eds): Practical and Theoretical Considerations in Preclinical and Clinical Studies. Berlin, Zentrale Universitätsdruckerei 1996, pp 187-204.
16. Saletu B: Pharmaco-EEG profiles of typical and atypical antidepressants; in E Costa, G Racagni (eds): Typical and Atypical Antidepressants. Clinical Practice. New York, Raven Press, pp 257-268.
17. Herrmann WM: Development and critical evaluation of an objective procedure for the electroencephalographic classification of psychotropic drugs; in Herrmann WM (ed): Electroencephalography in Drug Research. Stuttgart, Fischer, 1982, pp 249-352.
18. Goossens F, De Meester I, Wanhoof G, Scharpé S: A sensitive method for the assay of serum propyl endopeptidase. Eur J Clin Chem Clin Biochem 1992;30:235-238.
19. Dago KT, Luthringer R, Lengellé R, Rinaudo G, Macher JP: Statistical decision tree: a tool for studying pharmaco-EEG effects of CNS-active drugs. Neuropsychobiology 1994;29:91-96.
20. Itil TM, Eralp E, Tsambis E, Itil KZ, Stein U: Central nervous system effects of Ginkgo biloba, a plant extract. Am J Ther 1996;3:63-73.
21. Luthringer R, d'Ardigny P, Macher JP: Ginkgo biloba extract (Egb 761), EEG and event-related potentials mapping profile; in Christen Y, Courtois Y, Droy-Lefaix M-T (eds): Advances in Ginkgo biloba Extract Research. 4. Effects of Ginkgo biloba Extract (Egb 761) on Aging and Age-Related Disorders. Paris, Elsevier, 1995, pp 107-118.
22. Saletu B, Anderer P, Di Padova C, Assandri A, Saletu-Zyhlarz GM: Electrophysiological neuroimaging of the central effects of S-adenosyl- L-methionine by mapping of electroencephalograms and event-related po tentials and low-resolution brain electromagnetic tomography. Am J Clin Nutr 2002;76:1162S-1171S.
23. Saletu B, Grünberger J, Linzmayer L: Is amezinium metilsulfate - a new antihypotensive drug - psychoactive? Comparative quantitative EEG and psychometric trials with desipramine and methamphetamine. Curr Ther Res 1980;28:800-826.
24. Luthringer R, Dago KT, Patat A, Caille P, Curet O, Durieu G, Rinaudo G, Toussaint M, Granier LA, Macher JP: Pharmacoelectroencephalographic profile of befloxatone, a new reversible MAO-A inhibitor, in healthy subjects. Neuropsychobiology 1996;34:98-105.
25. Herrmann WM, Fuder H: Reboxetine, a selective noradrenaline reuptake inhibitor, is non-sedative and does not impair psychomotor performance in healthy subjects. Hum Psychopharmacol 1998;13:425-433.
26. Saletu B, Grünberger J: Classification and determination of cerebral bioavailability of fluoxetine: pharmacokinetic, pharmaco-EEG, and psychometric analyses. J Clin Psychiatry 1985;46:45-52.
27. Saletu B, Grünberger J: Early clinical pharmacological trials with a new antiepileptic, milacemide, using pharmaco-EEG and psychometry. Methods Find Exp Clin Pharmacol 1984;6:317-330.
28. Schulz I, Gerhartz B, Neubauer A, Holloschi A, Heiser U, Hafner M, Demuth MU: Modulation of inositol 1,4,5-triphosphate concentration by prolyl endopeptidase inhibition. Eur J Biochem 2002;269:5813-5820.